Financhill
Back

Genmab AS Quote, Financials, Valuation and Earnings

Genmab AS Price Quote

$20.31
+0.00 (+1.1%)
(Updated: December 21, 2024 at 5:28 AM ET)

Genmab AS Key Stats

Sell
19
Genmab AS (GMAB) is a Sell

Day range:
$20.13 - $20.43
52-week range:
$19.85 - $32.88
Dividend yield:
0%
P/E ratio:
21.18
P/S ratio:
4.58
P/B ratio:
2.7%

Volume:
1.8M
Avg. volume:
1.3M
1-year change:
-33.56%
Market cap:
$12.9B
Revenue:
$2.4B
EPS:
$1.05

How Much Does Genmab AS Make?

Data Unavailable

Is Genmab AS Growing As A Company?

Data Unavailable

Genmab AS Stock Price Performance

  • Did Genmab AS Stock Go Up Last Month?
    Genmab AS share price went down by -0.71% last month
  • Did GMAB's Share Price Rise Over The Last Year?
    GMAB share price fell by -33.56% over the past 1 year

What Is Genmab AS 52-Week High & Low?

  • What Is Genmab AS’s 52-Week High Share Price?
    Genmab AS has traded as high as $32.88 over the past 52 weeks
  • What Is Genmab AS’s 52-Week Low Share Price?
    Genmab AS has traded as low as $19.85 over the past 52 weeks

Genmab AS Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Genmab AS?

Data Unavailable

Is Genmab AS Cash Flow Positive?

Data Unavailable

Genmab AS Return On Invested Capital

Data Unavailable

Genmab AS Earnings Date & Stock Price

  • What Is Genmab AS's Stock Price Today?
    A single share of GMAB can be purchased today for 20.31
  • What Is Genmab AS’s Stock Symbol?
    Genmab AS trades on the nasdaq under the ticker symbol: GMAB
  • When Is Genmab AS’s Next Earnings Date?
    The next quarterly earnings date for Genmab AS is scheduled on May 8, 2025
  • When Is GMAB's next ex-dividend date?
    Genmab AS's next ex-dividend date is December 22, 2024
  • How To Buy Genmab AS Stock?
    You can buy Genmab AS shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Genmab AS Competitors

  • Who Are Genmab AS's Competitors?
    Below is a list of companies who compete with Genmab AS or are related in some way:
    • Ascendis Pharma AS (ASND)
    • Evaxion Biotech AS (EVAX)
    • Galecto Inc (GLTO)
    • IO Biotech Inc (IOBT)
    • Novo Nordisk AS (NVO)

Genmab AS Dividend Yield

Data Unavailable

Genmab AS Analyst Estimates

YoY Growth Past Surprise
EPS: -37.41% -12.85%
Revenue: 18.65% -0.87%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 36.56
Upside from Last Price: 80.03%

Major Shareholders

Data Unavailable